PRPF8 — pre-mRNA processing factor 8

The PRPF8 gene provides instructions for making a crucial protein that acts like a master organizer within the cell's machinery. This machinery, called the spliceosome, is responsible for "editing" the genetic messages copied from our DNA before they are used to build proteins. You can think of the spliceosome as a film editor that cuts out the unnecessary parts of a movie (introns) and splices the important scenes (exons) together so the final film makes sense. The PRPF8 protein sits at the very heart of this editing complex, ensuring that the genetic messages are cut and pasted accurately. When there is a mutation (a spelling mistake) in the PRPF8 gene, the editing machinery doesn't work perfectly. While this protein is used by every cell in the body, the cells in the retina—the light-sensitive tissue at the back of the eye—are particularly vulnerable to these editing mistakes. The retina requires a massive amount of perfectly edited genetic messages to function and survive. When the PRPF8 protein is faulty, errors build up, and the light-sensing cells (photoreceptors) gradually become damaged and die. For patients and families, a mutation in the PRPF8 gene causes a condition called Retinitis Pigmentosa (RP). This disease typically starts with night blindness in childhood or early adulthood, followed by a gradual loss of peripheral (side) vision, creating a "tunnel vision" effect. Over time, central vision can also be affected. PRPF8-related RP is inherited in an "autosomal dominant" pattern. This means that a person only needs one copy of the mutated gene (inherited from either parent) to develop the condition. Each child of an affected person has a 50% chance of inheriting the mutated gene and potentially developing the disease, though the severity can sometimes vary even within the same family.

Gene description: Encodes a core component of the U5 snRNP, which is critical for the catalytic step of pre-mRNA splicing within the spliceosome.

Patient and family guide: The PRPF8 gene provides instructions for making a crucial protein that acts like a master organizer within the cell's machinery. This machinery, called the spliceosome, is responsible for "editing" the genetic messages copied from our DNA before they are used to build proteins. You can think of the spliceosome as a film editor that cuts out the unnecessary parts of a movie (introns) and splices the important scenes (exons) together so the final film makes sense. The PRPF8 protein sits at the very heart of this editing complex, ensuring that the genetic messages are cut and pasted accurately. When there is a mutation (a spelling mistake) in the PRPF8 gene, the editing machinery doesn't work perfectly. While this protein is used by every cell in the body, the cells in the retina—the light-sensitive tissue at the back of the eye—are particularly vulnerable to these editing mistakes. The retina requires a massive amount of perfectly edited genetic messages to function and survive. When the PRPF8 protein is faulty, errors build up, and the light-sensing cells (photoreceptors) gradually become damaged and die. For patients and families, a mutation in the PRPF8 gene causes a condition called Retinitis Pigmentosa (RP). This disease typically starts with night blindness in childhood or early adulthood, followed by a gradual loss of peripheral (side) vision, creating a "tunnel vision" effect. Over time, central vision can also be affected. PRPF8-related RP is inherited in an "autosomal dominant" pattern. This means that a person only needs one copy of the mutated gene (inherited from either parent) to develop the condition. Each child of an affected person has a 50% chance of inheriting the mutated gene and potentially developing the disease, though the severity can sometimes vary even within the same family.

Gene function: PRPF8 is indispensable for the accurate and efficient splicing of pre-mRNA. In the retina, this gene's function is critical for the proper development and maintenance of photoreceptor cells and other retinal cell types. Dysfunctional PRPF8 can lead to widespread splicing defects, impacting the expression of numerous genes vital for retinal health, resulting in progressive vision impairment and blindness.

Protein structure: The PRPF8 protein is an exceptionally large and highly conserved macromolecule, consisting of 2,335 amino acids with a molecular weight of approximately 220 kDa. Structurally, it is organized into several distinct domains that facilitate its role as the central scaffold of the spliceosome. The N-terminal region contains a nuclear localization signal and domains that interact with other splicing factors. The central core of the protein, often referred to as the Large domain, forms a massive cavity that accommodates the RNA catalytic center of the spliceosome, directly binding to the U5 and U6 snRNAs and the pre-mRNA substrates. The C-terminal region of PRPF8 is particularly critical for its regulatory functions and is the site of most disease-causing mutations. This region includes an RNase H-like domain and a Jab1/MPN (Mpr1, Pad1 N-terminal) domain. The Jab1/MPN domain is a pseudo-enzyme structure that extends into a long, flexible C-terminal "tail." This tail structure is essential for the assembly and regulation of the spliceosome, as it inserts into the RNA-binding tunnel of the interacting Brr2 RNA helicase. By physically blocking or vacating this tunnel, the PRPF8 C-terminal tail acts as a switch to inhibit or stimulate Brr2 activity, precisely controlling the conformational rearrangements required for spliceosome activation.

Molecular function: The PRPF8 gene encodes the Pre-mRNA-processing-splicing factor 8, a massive and highly conserved 220-kDa protein that serves as the central scaffolding component of the spliceosome. The spliceosome is a dynamic, multi-megadalton ribonucleoprotein complex responsible for the excision of introns from precursor messenger RNAs (pre-mRNAs) and the ligation of exons, a critical step in gene expression. PRPF8 is a core component of the U5 small nuclear ribonucleoprotein (snRNP) and is essential for the assembly of the U4/U6.U5 tri-snRNP complex. At the molecular level, PRPF8 forms the catalytic core of the spliceosome. It interacts directly with the 5' and 3' splice sites of the pre-mRNA, the branch point sequence, and the U2, U5, and U6 snRNAs, positioning them precisely for the two transesterification reactions required for splicing. Furthermore, PRPF8 plays a crucial regulatory role by modulating the activity of the RNA helicase Brr2 (SNRNP200). The C-terminal Jab1/MPN domain of PRPF8 stimulates Brr2 helicase activity, while its C-terminal tail can inhibit Brr2 by blocking its RNA-binding tunnel. This fine-tuning is vital for the precise timing of spliceosome activation and disassembly. In the retina, the high transcriptional demand of photoreceptors makes them particularly sensitive to splicing efficiency. Mutations in PRPF8 disrupt its interaction with Brr2 or other spliceosomal components, leading to global changes in alternative splicing and splice site selection. This dysregulation particularly affects transcripts essential for ciliary function, apical-basal polarity, and cellular homeostasis in the retinal pigment epithelium (RPE) and photoreceptors, ultimately triggering the apoptotic pathways that lead to retinitis pigmentosa.

Expression pattern: The PRPF8 gene is ubiquitously expressed across all human tissues, consistent with its fundamental role as a core component of the spliceosome required for pre-mRNA splicing in all nucleated cells. High levels of expression are observed in the brain, reproductive organs, and various other tissues. In the context of the eye, PRPF8 is robustly expressed in the neural retina, particularly in the photoreceptor cells (both rods and cones), as well as in the retinal pigment epithelium (RPE). Despite its ubiquitous expression, mutations in PRPF8 predominantly cause a retina-specific phenotype (retinitis pigmentosa). This tissue-specific manifestation is thought to be due to the exceptionally high demand for pre-mRNA splicing in the retina. Photoreceptors have one of the highest metabolic and transcriptional rates in the body, requiring rapid and efficient turnover of transcripts for visual cycle proteins and outer segment renewal. Consequently, the retina may be uniquely vulnerable to subtle defects in spliceosome assembly or function caused by PRPF8 mutations, leading to the accumulation of splicing errors and eventual cell death.

Mutation spectrum: The mutation spectrum of the PRPF8 gene in retinitis pigmentosa is predominantly characterized by heterozygous missense mutations. These mutations are not randomly distributed but are highly clustered in a specific hotspot region at the extreme C-terminus of the protein, specifically within the Jab1/MPN domain and its extended tail (typically between amino acids 2300 and 2340). This region is critical for the interaction with and regulation of the Brr2 RNA helicase. In addition to missense mutations, a smaller number of frameshift, nonsense, and splice-site mutations have been identified, often resulting in an aberrantly prolonged or truncated C-terminus. Large deletions are rare. Currently, there are several dozen known pathogenic variants in PRPF8 associated with adRP. While PRPF8 mutations are a relatively rare cause of adRP overall (accounting for approximately 2-3% of cases in various populations), the clustering of mutations in the C-terminal domain highlights the critical functional importance of this specific region in maintaining retinal health.

Pathogenic variants: 1. p.His2309Pro (c.6926A>C) - One of the most frequently reported and well-characterized pathogenic variants, located in the C-terminal hotspot. It disrupts the interaction with the Brr2 helicase and is associated with a classic, often severe, adRP phenotype. 2. p.Tyr2334Asn (c.7000T>A) - A missense mutation in the extreme C-terminus that causes a severe clinical phenotype with early macular involvement. It has been shown to impair alternative splicing and cause photoreceptor defects in models. 3. p.Arg2310Gly (c.6928A>G) - Another common missense mutation in the C-terminal hotspot, known to cause adRP by likely destabilizing the regulatory interaction between PRPF8 and Brr2. 4. p.Ser2118Phe (c.6353C>T) - A nonconservative missense mutation associated with marked intrafamilial variability, ranging from severe rod-cone dystrophy to mild, late-onset phenotypes and incomplete penetrance. 5. p.Glu2331ValfsX15 - A frameshift mutation near the C-terminus that results in an aberrantly extended protein. This type of mutation mimics the effects of missense variants in the region, leading to splicing dysregulation and adRP.

Clinical significance: Mutations in the PRPF8 gene are a well-established cause of autosomal dominant retinitis pigmentosa (adRP), specifically designated as RP13. Clinically, PRPF8-associated adRP is characterized by the progressive degeneration of rod photoreceptors followed by cone photoreceptors. Patients typically present with nyctalopia (night blindness) in childhood or adolescence, which is often the first symptom. As the disease progresses, individuals experience a gradual constriction of their visual fields, leading to tunnel vision, and eventually, a decline in central visual acuity. The severity and age of onset of PRPF8-related adRP can be highly variable, even among affected individuals within the same family. While some patients experience severe, early-onset rod-cone dystrophy leading to legal blindness in mid-adulthood, others may have a milder phenotype with preserved central vision and only mild rod dysfunction well into their later years. This marked intrafamilial variability and instances of incomplete penetrance suggest that other genetic or environmental modifiers may influence the clinical expression of PRPF8 mutations. Despite being a ubiquitously expressed gene essential for cellular function in all tissues, PRPF8 mutations primarily manifest as a non-syndromic retinal dystrophy, though rare associations with neurodevelopmental disorders have been suggested.

Inheritance: Autosomal Dominant

Chromosomal location: 17p13.3

Genotype-phenotype correlations: Genotype-phenotype correlations in PRPF8-associated retinitis pigmentosa are complex and not fully elucidated, largely due to the rarity of the condition and the marked clinical variability observed even among individuals with the same mutation. Most pathogenic variants in PRPF8 are missense mutations clustered in the highly conserved C-terminal region, particularly within the Jab1/MPN domain and its tail extension. Mutations in this region, such as p.His2309Pro or p.Tyr2334Asn, often result in a severe phenotype with early-onset night blindness and rapid progression of visual field loss. However, significant intrafamilial variability has been documented. For example, families carrying the p.Ser2118Phe or p.Arg2310Ser mutations have shown phenotypes ranging from severe, early-onset rod-cone dystrophy to very mild, late-onset disease, and even incomplete penetrance where individuals carrying the mutation remain asymptomatic. This variability suggests that the specific amino acid change alone does not strictly dictate the clinical outcome. It is hypothesized that the differential impact of specific mutations on the interaction between PRPF8 and the Brr2 helicase, or the presence of modifying genetic factors, may modulate the severity of the splicing defect and, consequently, the clinical phenotype. Frameshift mutations and nonconservative amino acid changes generally tend to correlate with more severe clinical presentations.

Research and therapeutic approaches: Currently, there are no FDA-approved therapies specifically targeted at curing or halting the progression of PRPF8-associated retinitis pigmentosa. Management remains supportive, focusing on maximizing remaining vision through low-vision aids, orientation and mobility training, and regular ophthalmologic monitoring to manage complications such as cataracts or macular edema. Vitamin A supplementation is sometimes considered for RP generally, but its efficacy is debated and it must be carefully monitored. Research into therapeutic approaches for PRPF8 and other splicing factor-related IRDs is actively ongoing in preclinical stages. Because PRPF8-adRP is caused by dominant, likely gain-of-function or dominant-negative mutations, traditional gene augmentation therapy (adding a healthy copy of the gene, as is done with Luxturna for RPE65) is challenging and may not be sufficient. Instead, strategies are focusing on gene editing technologies, such as CRISPR/Cas9, to specifically knock out the mutant allele while preserving the wild-type allele, or to correct the mutation directly. Other investigational approaches include the use of antisense oligonucleotides (ASOs) to modulate splicing or downregulate the mutant transcript. Additionally, neuroprotective agents and small molecules that aim to reduce cellular stress, improve spliceosome function, or prevent apoptosis are being explored in animal models and retinal organoids. While clinical trials for gene therapies targeting other RP genes are underway, specific trials for PRPF8 are still in the pipeline, awaiting further validation of these targeted strategies in robust animal and cellular models.

Diagnostic testing: Diagnostic testing for PRPF8-associated retinitis pigmentosa typically involves molecular genetic testing. Given the genetic heterogeneity of inherited retinal diseases (IRDs), multi-gene panel testing that includes PRPF8 and other known adRP genes is the most common and efficient approach. These panels use next-generation sequencing (NGS) to identify single nucleotide variants, small insertions/deletions, and sometimes copy number variations. If panel testing is inconclusive, comprehensive genomic testing such as whole exome sequencing (WES) or whole genome sequencing (WGS) may be considered to identify novel or rare variants. Genetic counseling is a critical component of the diagnostic process. Because PRPF8 mutations are inherited in an autosomal dominant manner, each child of an affected individual has a 50% chance of inheriting the pathogenic variant. Genetic counselors can help families understand the inheritance pattern, the variable expressivity and potential for incomplete penetrance associated with PRPF8 mutations, and the implications for family planning. They also provide guidance on the psychological and social aspects of living with a progressive blinding condition and can connect patients with clinical trials and support resources.

Animal models: Animal models have been crucial in understanding the pathophysiology of PRPF8-related retinitis pigmentosa. Mouse models, such as the Prpf8 p.His2309Pro (H2309P) knock-in mouse, have been developed to mimic human mutations. While homozygous H2309P mice are viable, they exhibit late-onset, mild retinal degeneration, indicating that the mutation does not cause a complete loss of function but rather a specific defect in retinal maintenance. More recently, the Prpf8 p.Tyr2334Asn (Y2334N) substitution and a frameshift variant (Prpf8Δ17) have been modeled in mice. Interestingly, these models showed progressive cerebellar neurodegeneration and granule cell loss, highlighting the sensitivity of specific neuronal populations to spliceosomal defects, though retinal phenotypes can vary depending on the specific mutation and genetic background. Zebrafish models have also been utilized to study PRPF8 function. Zebrafish prpf8 mutants exhibit defects in early development, including brain and head formation, and have been used to study the role of splicing factors in motile cilia dysfunction and laterality establishment. These models underscore the systemic importance of PRPF8 during development and provide a platform for high-throughput drug screening and studying the molecular mechanisms of photoreceptor degeneration and replacement.

Population genetics: Mutations in the PRPF8 gene are a rare cause of retinitis pigmentosa, accounting for approximately 2% to 3% of all autosomal dominant RP (adRP) cases in various populations, including European, American, and Asian cohorts. Because it is a rare, dominantly inherited condition, the concept of a general "carrier frequency" is less applicable than for recessive diseases; individuals with a pathogenic variant are typically affected by the disease, subject to penetrance. There are no widely recognized major founder mutations for PRPF8 that cause a high prevalence in specific ethnic groups, though certain variants may be seen more frequently in localized populations due to familial inheritance. The overall prevalence of PRPF8-associated adRP in the general population is extremely low, reflecting the rarity of the condition.

Selected references: 1. McKie AB, et al. Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). Hum Mol Genet, 2001. PMID: 11487574 2. Mozaffari-Jovin S, et al. Inhibition of RNA helicase Brr2 by the C-terminal tail of the spliceosomal protein Prp8. Science, 2013. PMID: 23828938 3. Towns KV, et al. Prognosis for splicing factor PRPF8 retinitis pigmentosa, novel mutations and correlation between human and yeast phenotypes. Hum Mutat, 2010. PMID: 20340136 4. Graziotto JJ, et al. Three gene-targeted mouse models of RNA splicing factor RP show late-onset RPE and retinal abnormalities. Invest Ophthalmol Vis Sci, 2011. PMID: 20811066 5. Arzalluz-Luque Á, et al. Mutant PRPF8 Causes Widespread Splicing Changes in Spliceosome Components in Retinitis Pigmentosa Patient iPSC-Derived RPE Cells. Front Neurosci, 2021. PMID: 33994920 6. Krausová M, et al. Retinitis pigmentosa-associated mutations in mouse Prpf8 cause misexpression of circRNAs and degeneration of cerebellar granule cells. Life Sci Alliance, 2023. PMID: 37019515 7. Atkinson R, et al. PRPF8-mediated dysregulation of hBrr2 helicase disrupts splicing and apical-basal polarity in RP13 patient-derived retinal cells. Nat Commun, 2024. PMID: 38580643